Sponsored Links

 

Displaying crizotinib PowerPoint Presentations



Lessons From Clinical Trials of Targeted Therapies for Cancer PPT

Presentation Summary : Dumb Tumors vs. Smart Tumors Clinical Trial Implications of Biomarker-Driven Therapy Slide 17 The Crizotinib Story: How It’s Supposed to Work Crizotinib: ...

Source : http://oplinc.com/Uploaded-Files/Sledge.ppt

Targeted Therapy for Metastatic NSCLC PPT

Presentation Summary : Crizotinib is better than chemotherapy for ALK-positive patients. 2nd Generation ALK inhibitors are being tested. Immune therapies (anti-PD1) may work in lung cancer.

Source : http://sumocancer.org/documents/Targeted%20Therapy%20for%20Metastatic%20NSCLC%20(Gregory%20Riely%20MD%20PhD).pptx

PowerPoint Presentation PPT

Presentation Summary : ... * * * Natural selection of resistant clones while most disease still controlled by crizotinib Baseline: July 2009 Crizotinib response:Sept 2009 November ...

Source : http://l39gg632kcb0ewpfj-sites-default-files.s3.amazonaws.com/0830%20Camidge%20v2.ppt

Therapeutic Decision Making in Advanced NSCLC: A 2012 Perspective PPT

Presentation Summary : ... (FDA-approved test) IHC RT-PCR Activity of ALK Inhibitor Crizotinib in Patients With Advanced ALK-FISH–Positive NSCLC (N = 82) Shaw AT, et al. ASCO 2011.

Source : http://s3.amazonaws.com/AdvancedNSCLC2012/CCO_Advanced_NSCLC_Decisions_2012_Slides.ppt

PowerPoint Presentation PPT

Presentation Summary : Crizotinib. AP26113. EML4-ALK-L1196M. EML4-ALK. ALK-negative cells. Drug Concentration (nM) Relative Cell Viability. Ba/F3 cells (ALK-negative) engineered to express ...

Source : http://elcon.imedex.com/ELC/2012/6373/0930_Shaw_New.pptx

PowerPoint Presentation PPT

Presentation Summary : 50 YO woman with ALK+ NSCLC Treated with Crizotinib September 2011 September 2012 Efficacy of Crizotinib in Patients with EML4-ALK Rearrangements Kwak ...

Source : http://www.aats.org/LungCancer/presentations/2012/0855%20Johnson.ppt

PowerPoint Presentation PPT

Presentation Summary : ALK positive patients are sensitive to crizotinib. Significant fraction of ALK+ patients were enrolled in crizotinib trials with excellent response

Source : http://www.oncoletter.ch/fileupload/MariellaGarcia.pptx

Slide 1 PPT

Presentation Summary : Crizotinib (PF-02341066) Part 2: Molecularly defined cohorts Part 1: Dose escalation (n=37) Crizotinib: First-in-human/Patient Trial (A8081001) ...

Source : http://www.scientificorganizingservice.com/public/L.ppt

Molecular Management of Advanced NSCLC - Imedex, LLC PPT

Presentation Summary : Crizotinib – active in ALK/ROS1 translocated patients, ? met amplification/mutated. BRAF mutations – vemurafenib, dabrafenib. Studies ongoing with specifically ...

Source : http://elcon.imedex.com/ELC/2013/6699/1000_Socinski.pptx

Title of Module/Lecture - ANCO On-Line PPT

Presentation Summary : ... 7503- EURTAC, 7505- MetMab, 7507-crizotinib, 7500-ganetespib Early Stage NSCLC 7002-TREAT, 7013-E1505 Small Cell Lung Cancer 7000-amrubicin, ...

Source : http://www.anco-online.org/Wakelee2011.ppt

Learning Objectives - Kentucky Cancer Registry PPT

Presentation Summary : Crizotinib. Negative: No Crizotinib. ALK FISH testing. Molecular Testing in NSCLC. Who should be tested? Which stage? Which test? What material? EGFR mutation testing?

Source : http://www.kcr.uky.edu/training/fall12/KCR%20talk%20Arnold.pptx

PowerPoint Presentation PPT

Presentation Summary : There was a study presented at ASCO this year looking at the visual effects in ALK positive patients treated with crizotinib.

Source : http://www.oncologyclinicsvictoria.com.au/sites/default/files/nsclc.pptx

HSP 90 Inhibitors in Lung Cancer - Winship Cancer Institute ... PPT

Presentation Summary : Next steps Combination of Crizotinib with Hsp90 inhibitors Hsp90 inhibition in Crizotinib-resistant ALK +NSCLC Hsp90 Inhibition in NSCLC It is likely that other ...

Source : https://winshipcancer.emory.edu/media/file/Sea%20Island%202011/Thursday%206_%20Ramalingam%20%202011%20novel%20agents.ppt

Diapositiva 1 - Oncologia Toracica PPT

Presentation Summary : ... -TKIs in naïve patients ALK-TKIs in crizotinib-refractory disease Challenging brain mets in ALK+ disease Resistance to crizotinib: ...

Source : http://www.oncologiatoracica.it/public/crinoMilano%20POST%20IASLC.ppt

Lung Cancer - Lafayette Medical Education Foundation, INC PPT

Presentation Summary : ... + chemotherapy in pts with good performance status Erlotinib is first line therapy in pts with EGFR mutation Crizotinib is first line therapy in pts who are ...

Source : http://www.lafmeded.org/Lung-Cancer-2.ppt

Diapositiva 1 - AIOM PPT

Presentation Summary : ... Crizotinib (PF-02341066), in Patients with ALK-positive Non-small Cell Lung Cancer Potential Oncogenic “Drivers” in Non-small Cell Lung Cancer ...

Source : http://www.aiom.it/C_Common/Download.asp?file=/$Site$/Eventi_Congressi/VirtualMeeting/AIOM-ASCO-2010/10_Lucio_Crino.ppt

The first 12 months of UK diagnostic services for EGFR gene ... PPT

Presentation Summary : ... Crizotinib FISH (IHC, PCR) Crizotinib and EML4- ALK fusions ~4.5% adenocarcinoma patients Dramatic response to therapy Analysis by FISH, IHC or PCR ...

Source : http://www.rcpath.org/Resources/MSPowerpoint/Dr%20R%20Butler.ppt

Sponsored Links
If you find powerpoint presentation a copyright It is important to understand and respect the copyright rules of the author.
Please do not download if you find presentation copyright.
If you find a presentation that is using one of your presentation without permission, contact us immidiately at

© XPowerPoint.com